Prescription drug · NDA
Vyndamax (Tafamidis) NDC 0069-8730
Tafamidis 61 mg/1 · Capsule, Liquid filled · Oral · Pfizer Laboratories Div Pfizer Inc
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0069-8730-30 | 00069873030 | 30 BLISTER PACK in 1 CARTON (0069-8730-30) / 1 CAPSULE, LIQUID FILLED in 1 BLISTER PACK (0069-8730-01)Marketed from Aug 27, 2019 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Vyndamax
- Generic name (nonproprietary)
- tafamidis
- Active ingredients
- Tafamidis — 61 mg/1
- Dosage form
- Capsule, Liquid filled
- Route
- Oral
- Labeler
- Pfizer Laboratories Div Pfizer IncNDC labeler code 0069
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 212161
- Marketing start
- Listing expires
- Identifiers
- Product ID 0069-8730_67f1031d-c298-4cf9-9051-bb8f99e56442SPL ID 67f1031d-c298-4cf9-9051-bb8f99e56442SPL set ID 1b4121ee-a733-4456-a917-be2603477839RxCUI 2168534, 2168540, 2168542, 2168548UNII ZU7CF08A1A, 8FG9H9D31J
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400069873030followed by a unit qualifier and the quantityPackage 00069-8730-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
1. INDICATIONS AND USAGE VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 0069-8730
- What is NDC 0069-8730?
- 0069-8730 is the product NDC for Vyndamax (tafamidis), Tafamidis 61 mg/1 capsule, liquid filled, listed with the FDA by Pfizer Laboratories Div Pfizer Inc. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Vyndamax (Tafamidis).
- What is the active ingredient?
- Tafamidis.
- Who is the labeler?
- Pfizer Laboratories Div Pfizer Inc, NDC labeler code 0069. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Vyndamax?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.